Alteplase for treating acute ischaemic stroke
KEYWORDS: alteplase, stroke, manufacturer, treatment, committee, patients, hour, acute, ischaemic, window, hours, model, ischaemic stroke, acute ischaemic, death

in the dead state (8.19%). This sensitivity analysis resulted in an ICER of £4,451 per QALY gained for alteplase compared with standard care for the 0- to 4.5-hour window (incremental costs £698; incremental QALYs 0.157). 3.25 Full details of all the evidence are in the manufacturer's submission and the ERG report. Alteplase for treating acute ischaemic stroke (TA264) 4 Consideration of the evidence 4.1 The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of alteplase, having considered evidence on the nature of acute ischaemic stroke and the value placed on the benefits of alteplase by people with the condition, those who represent them, and clinical specialists. It also took into account the effective use of NHS resources. 4.2 The Committee discussed the place of alteplase in the clinical pathway for people who have had an acute ischaemic stroke. The Committee heard from the clinical specialists that alteplase is routinely used in the NHS in England and Wales in patients aged 18 to 80 years within 4.5 hours of onset of symptoms. The Committee was aware of the recently published third International Stroke Trial (IST-3), an open-label trial comparing alteplase with standard care. However, the Committee noted
